Alebund Pharmaceuticals (Jiangsu) Limited
Research Alebund Pharmaceuticals (Jiangsu) Limited (9637.HK) on Bullrun: market cap HKD 6.09B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker9637.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryDrug Manufacturers - General
- CurrencyHKD
- Market capHKD 6.09B
- Financial periodFY2025
- RevenueCNY 30.56M
- Revenue growth368.3%
- Net income-CNY 750.04M
- Free cash flow-CNY 389.51M
- Gross margin44.0%
Valuation Snapshot
latest market cap is HKD 6.09B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 30.56M | -CNY 750.04M | -CNY 389.51M | 44.0% | -2.21 | CNY 358.33M | CNY 549.42M | CNY 503.24M |
| FY2024 | CNY 6.53M | -CNY 326.03M | -CNY 486.56M | 36.6% | -0.96 | CNY 343.77M | CNY 479.15M | -CNY 1.33B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 6.09B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About Alebund Pharmaceuticals (Jiangsu) Limited
Alebund Pharmaceuticals (Jiangsu) Limited operates as a biopharmaceutical company that develops therapies for kidney diseases and their complications in China and Hong Kong. Its products include AP301, a phosphate binder; AP306, a sodium-dependent phosphate transport protein inhibitor; one early-clinical-stage product candidate AP303; and four preclinical product candidates, including AP308, AP304, AP305, and AP307.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Alebund Pharmaceuticals (Jiangsu) Limited's market cap?
Alebund Pharmaceuticals (Jiangsu) Limited's market capitalization is HKD 6.09B.
What does Alebund Pharmaceuticals (Jiangsu) Limited do?
Alebund Pharmaceuticals (Jiangsu) Limited operates as a biopharmaceutical company that develops therapies for kidney diseases and their complications in China and Hong Kong. Its products include AP301, a phosphate binder; AP306, a sodium-dependent phosphate transport protein inhibitor; one early-clinical-stage product candidate AP303; and four preclinical product candidates, including AP308, AP304, AP305, and AP307. Alebund Pharmaceuticals (Jiangsu) Limited was founded in 2018 and is headquartered in Yangzhou, China.